key: cord-0993514-8zt0x518
authors: Ali, Amira Mohammed; Kunugi, Hiroshi
title: Hypoproteinemia predicts disease severity and mortality in COVID-19: a call for action
date: 2021-04-13
journal: Diagn Pathol
DOI: 10.1186/s13000-021-01092-5
sha: eb121cc7f4dcd1f5c1978d588d6944315003db4b
doc_id: 993514
cord_uid: 8zt0x518

Proteins represent the major building blocks of body tissues, and they regulate signaling involved in most cellular activities. Coronavirus disease 2019 (COVID-19) infection has been associated with high fatality, especially among older adults. The main cause of death is pulmonary tissue damage and multiple organ failure. The disease is associated with a hypercatabolic state that entails excessive protein loss. This review commentary sheds the light on hypoproteinemia in symptomatic/hospitalized COVID-19 with a special emphasis on its pathophysiology, screening, as well as its contribution to disease severity and adverse effects.

Coronavirus disease 2019 (COVID-19) pathology activates severe protein catabolism resulting in extensive wasting and loss of skeletal muscle mass [1] . Skeletal muscle is a major protein store that contributes to the regulation of metabolism of the whole body [2] . Body protein degradation is evident in severe and critical COVID-19 patients; they manifest low serum levels of total protein, albumin, prealbumin, and high levels of blood urea nitrogen (BUN) [3] [4] [5] [6] . BUN is a nitrogenous end product of protein metabolism, and it is associated with mortality in numerous diseases [6] . Protein loss impedes immune functioning and exacerbates symptoms in COVID-19 [3] [4] [5] [6] [7] .

Critical COVID-19 patients exhibit a crude mortality rate of 49% [6] . The available literature shows that hypoalbuminemia in COVID-19 patients is associated with progression to more severe stages of the illness involving increased need for hospitalization, transfer to intensive care unit (ICU), mechanical ventilation, and nutritional support, in addition to increased mortality [3] [4] [5] 7] . In a study comparing blood levels of C-reactive protein, lactate dehydrogenase (LDH), D-dimer, albumin, ferritin, and cardiac troponin T between patients not admitted to the ICU vs ICU admitted and between survivors vs non-survivors, only albumin < 18 g/L and LDH > 731 U/ L significantly predicted mortality in an adjusted multivariate analysis while LDH < 425 U/L was associated with lower rates of ICU admission [4] .

Low albumin and associated mortality correlate with the cytokine storm, old age, male gender, hospital admission, and comorbid diabetes mellitus [3, [5] [6] [7] . Several measures used to predict COVID-19 prognosis depend primarily on albumin level along with some of these characteristics [1, 5] . By using a tree-based machine learning model, Zhou et al. [5] identified the most informative characteristics and hidden interactions that can predict ICU admission in COVID-19 patients: low red blood cell count, male gender, older age, low albumin, low sodium, and prolonged activated partial thromboplastin time (APTT). That model demonstrated precision of 0.91 with an area under the curve (AUC) of 0.92 [5] . Serum albumin may facilitate the detection of malnutrition in COVID-19 when combined with weight changes (e.g., Nutritional Risk Index), total lymphocyte count (e.g., Prognostic Nutritional Index), or with both lymphocyte count and total cholesterol (e.g., the controlling nutritional status score) [2, 8] .

Cheng et al. [6] developed a nomogram model based on a combination of initial BUN ≥4.6 mmol/L and Ddimer ≥0.845 μg/mL to identify patients at high risk for in-hospital mortality. The AUC for this model was 0.94 (95% CI 0.90-0.97), with a sensitivity of 85% and specificity of 91% [6] . BUN (adjusted hazard risk (AHR) = 1.06, 95% CI 1.03-1.09; P < 0.0001) and Ddimer (AHR = 1.11, 95% CI 1.08-1.14; P < 0.0001) remained significantly associated with in-hospital mortality in multivariable analysis adjusted for age, sex, comorbidity, neutrophil count, lymphocyte count, platelet count, albumin, LDH, procalcitonin, and interleukin-6 [6] .

Reasons why hypoproteinemia develops in COVID-19 remain unclear. Anorexia/vomiting and diarrhea, in order, are reported in 25.8 and 29.8% of all COVID-19 patients [6] . Inadequate food supply secondary to these symptoms may direct the body toward protein breakdown for energy production [2] . The degradation of body protein is a result of a complex interaction between inflammatory cytokines, reactive oxygen species, and insulin insensitivity [1, 2] . The inflammatory interactions of the virus that causes COVID-19, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), with human cells induce dysregulation of signaling involved in glucose metabolism resulting in decreased sensitivity to insulin and hyperglycemia signifying inability of the body to use glucose as a source of energy [9] . Hyperglycemia and inflammation potentiate glycation stress, which potentiates the formation of toxic metabolites that accelerate inflammation and oxidative stress (i.e., vicious cycle), eventually leading to damage of cellular protein and lipid structures [2] . Skeletal muscle disuse associated with ICU admission as well as mechanical ventilation accelerate the breakdown of skeletal muscle protein leading to severe hypoproteinemia over a short period of time [1] .

Several studies show that hypoproteinemia in COVID-19 is associated with excessive elevation of inflammatory cytokines as well as parameters of coagulopathy (e.g., prolonged APTT, D-dimer, prothrombin time, and activated partial thromboplastin) [3, [5] [6] [7] -suggesting that liver damage secondary to hypercytokinemia triggers hypoproteinemia, which furthers inflammation and leads to death [3] . Indeed, liver damage in hospitalized COVID-19 patients is high (58% on admission), and it is associated with multiple organ failure, acute renal damage, increased ICU admission, need for mechanical ventilation, and mortality [10] .

In summary, hypoproteinemia in COVID-19 is associated with the cytokine storm, multiple organ failure, disease severity, and disease-related mortality. Biomarkers of hypoproteinemia (e.g., albumin and BUN) are clearly predictive for COVID-19 outcomes. Clinicians should pay more attention to these markers and intervene accordingly at an early stage, which will prevent progression to severe stages of the illness. 

Approaches to nutritional screening in patients with Coronavirus Disease 2019 (COVID-19)

Age-related skeletal muscle failure (sarcopenia)-a detrimental challenge during the Coronavirus Disease 2019 (COVID-19) era: A review

Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2,623 hospitalized cases

A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity

Identifying main and interaction effects of risk factors to predict intensive care admission in patients hospitalized with COVID-19: a retrospective cohort study in Hong Kong

Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients

Evaluation of Nutrition Risk and Its Association With Mortality Risk in Severely and Critically Ill COVID-19 Patients

Evaluation of the nutritional status in patients with COVID-19

Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis

Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

None.

Both authors conceptualized the topic, wrote, and revised the manuscript. The authors read and approved the final manuscript.

This study was supported by the Strategic Research Program for Brain Sciences from Japan Agency for Medical Research and development, AMED, Japan (Grant No. 18dm0107100h0003).

Not applicable. 

Ethics approval and consent to participate Not applicable.

Not applicable.

The authors declare no conflict of interest.Author details